| Attributes | Values |
|---|
| rdf:type
| |
| Description
| - Silymarin má díky svým hypolipidemickým účinkům pozitivní vliv na rizikové faktory atherosklerosy. PPARa hraje zásadní roli v metabolismu a homeostáze lipidů, jelikož mezi cílové geny tohoto receptoru patří enzymy zasahující do katabolismu mastných kyselin beta-oxidací (např. acyl-coA oxidasa) či omega-oxidací (cytochrom P450 4A). V této práci byla zkoumána možnost, že hypolipidemické vlastnosti silymarinu jsou zprostředkovány receptorem PPARa. Potkani byli krmeni vysokocholesterolovou dietou s obsahem buď silymarinu nebo fenofibrátu (jako pozitivní kontroly pro expresii PPARa i pro měření hladiny lipidů). Byla měřena jaterní exprese PPARa na úrovni mRNA (včetně vybraných cílových genů) i na úrovni proteinu. Paralelně byly také měřeny hladiny cholesterolu a triacylglycerolů. Naše výsledky potvrzují hypolipidemické účinky silymarinu a ukázují, že tyto pravděpodobně nejsou zprostředkovány receptorem PPARa díky nezměněné hladině mRNA cílových genů PPARa. Navíc tato práce jako první poukazuje na schopnost (cs)
- Silymarin is widely used in supportive therapy of liver diseases. It has been shown lately that silymarin has beneficial effects on some risk factors of atherosclerosis owing to its hypolipidemic properties. PPARα plays a key role in lipid metabolism and homeostasis as its target genes are involved in catabolism of fatty acids by β-oxidation (e.g. acyl-CoA oxidase) and by ω-oxidation (e.g. cytochrome P4504A). Here we studied the possibility that hypolipidemic effects of silymarin may be mediated by PPARα. Rats fed with a high-cholesterol diet with either silymarin or fenofibrate (as a positive control both for PPARα expression as well as for lipid determination) were used. The effects of silymarin on expression of PPARα both at the mRNA (including selected target genes) as well as the protein level were determined. In parallel, the levels of cholesterol and triacylglycerols were determined. Our results confirmed the hypolipidemic effects of silymarin and demonstrated that
- Silymarin is widely used in supportive therapy of liver diseases. It has been shown lately that silymarin has beneficial effects on some risk factors of atherosclerosis owing to its hypolipidemic properties. PPARα plays a key role in lipid metabolism and homeostasis as its target genes are involved in catabolism of fatty acids by β-oxidation (e.g. acyl-CoA oxidase) and by ω-oxidation (e.g. cytochrome P4504A). Here we studied the possibility that hypolipidemic effects of silymarin may be mediated by PPARα. Rats fed with a high-cholesterol diet with either silymarin or fenofibrate (as a positive control both for PPARα expression as well as for lipid determination) were used. The effects of silymarin on expression of PPARα both at the mRNA (including selected target genes) as well as the protein level were determined. In parallel, the levels of cholesterol and triacylglycerols were determined. Our results confirmed the hypolipidemic effects of silymarin and demonstrated that (en)
|
| Title
| - Hypolipidemic effects of silymarin are not mediated by the peroxisome proliferator-activated receptor alpha
- Hypolipidemic effects of silymarin are not mediated by the peroxisome proliferator-activated receptor alpha (en)
- Hypolipidemické účinky silymarinu nejsou zprostředkovány peroxisomovými proliferátory-aktivovaným receptorem alfa (cs)
|
| skos:prefLabel
| - Hypolipidemic effects of silymarin are not mediated by the peroxisome proliferator-activated receptor alpha
- Hypolipidemic effects of silymarin are not mediated by the peroxisome proliferator-activated receptor alpha (en)
- Hypolipidemické účinky silymarinu nejsou zprostředkovány peroxisomovými proliferátory-aktivovaným receptorem alfa (cs)
|
| skos:notation
| - RIV/61989592:15110/07:00004221!RIV08-MSM-15110___
|
| http://linked.open.../vavai/riv/strany
| |
| http://linked.open...avai/riv/aktivita
| |
| http://linked.open...avai/riv/aktivity
| - P(1P05OC065), Z(MSM6198959216)
|
| http://linked.open...iv/cisloPeriodika
| |
| http://linked.open...vai/riv/dodaniDat
| |
| http://linked.open...aciTvurceVysledku
| |
| http://linked.open.../riv/druhVysledku
| |
| http://linked.open...iv/duvernostUdaju
| |
| http://linked.open...titaPredkladatele
| |
| http://linked.open...dnocenehoVysledku
| |
| http://linked.open...ai/riv/idVysledku
| - RIV/61989592:15110/07:00004221
|
| http://linked.open...riv/jazykVysledku
| |
| http://linked.open.../riv/klicovaSlova
| - Silymarin; PPARα; Cholesterol; Cytochrome P4504A (en)
|
| http://linked.open.../riv/klicoveSlovo
| |
| http://linked.open...odStatuVydavatele
| - GB - Spojené království Velké Británie a Severního Irska
|
| http://linked.open...ontrolniKodProRIV
| |
| http://linked.open...i/riv/nazevZdroje
| |
| http://linked.open...in/vavai/riv/obor
| |
| http://linked.open...ichTvurcuVysledku
| |
| http://linked.open...cetTvurcuVysledku
| |
| http://linked.open...vavai/riv/projekt
| |
| http://linked.open...UplatneniVysledku
| |
| http://linked.open...v/svazekPeriodika
| |
| http://linked.open...iv/tvurceVysledku
| - Anzenbacher, Pavel
- Orolin, Jan
- Večeřa, Rostislav
- Škottová, Nina
- Jung, D.
- Meyer, U. A.
|
| http://linked.open...n/vavai/riv/zamer
| |
| issn
| |
| number of pages
| |
| http://localhost/t...ganizacniJednotka
| |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)